Brief: Hybrigenics announces results from Phase II study on inecalcitol

Aton SA

09/02/2017 17:03

Feb 9 (Reuters) - Hybrigenics SA  ALHYG.PA : 
    * Announces encouraging preliminary results from the Phase 
II clinical study of inecalcitol in Chronic Myelogenous Leukemia 
    * At this intermediate stage of study, 43 percent of the 
patients (6 out of 14) have shown further decrease in bcr-abl 
from mmr at three months 
    * After one year of treatment, 33 percent (3 out of 9) have 
demonstrated reduction in BCR-ABL beyond DMR, i.e. undetectable 
biomarker traces 
    * The sample size of this pilot study has been reduced to 42 
patients, with a target completion in H2 2018 
 
Source text: http://bit.ly/2k8iSuO 
Further company coverage:  ALHYG.PA  
 
 (Gdynia Newsroom) 
 ((gdynia.newsroom@thomsonreuters.com; +48 58 772 0920;))